Robert Schmouder

6.7k citations

93 papers · 5.4k indexed · 2 hit papers · h-index 32

Impact in

Transplantation top 0.2%
- Renal Transplantation Outcomes and Treatments
Nephrology top 1%

Papers in

Transplantation 24
- Renal Transplantation Outcomes and Treatments 24
Nephrology 12

Co-authors: Akinlolu Ojo Friedrich K. Port Philip J. Held Robert A. Wolfe John M. Kovarik Volker Brinkmann Peter Heining Andreas Billich
Journals: Transplantation (18 papers)The Journal of Clinical Pharmacology (10 papers)Blood (6 papers)Journal of Hypertension (4 papers)British Journal of Clinical Pharmacology (4 papers)
Partner nations: United States Switzerland Germany

In The Last Decade

Robert Schmouder

89 papers receiving 5.3k citations

Hit Papers

align trajectories log scale

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis 2010 · 1.0k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Nature Reviews Drug Discovery
1997 Transplantation

Peers

Countries citing papers authored by Robert Schmouder

Since Specialization

Citations

This map shows the geographic impact of Robert Schmouder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Schmouder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Schmouder more than expected).

Fields of papers citing papers by Robert Schmouder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Schmouder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Schmouder. The network helps show where Robert Schmouder may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Schmouder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Schmouder Line = papers co-authored together Robert Schmouder links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals Clinical and Translational Science ·Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy, Elizabeth McNamara, Danielle Armas, Venkateswar Jarugula, Robert Schmouder	2025	0
2	Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis Alimentary Pharmacology & Therapeutics ·Juan P. Frías, Robert Schmouder, Eric Lawitz, Yiming Zhang, Heng Zhou, Michael K. Badman, Chinweike Ukomadu, H. Weiss, Julia Zack, Brijesh Yadav, Miljen Martić, Clive Drakeford, Phillip J. Koo, Nikolai V. Naoumov, Linda E. Greenbaum	2025	1
3	Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function Clinical Pharmacology & Therapeutics ·Elise Burmeister Getz, Richard R. Stein, Martin Fink, Kenneth Kulmatycki, Irina Baltcheva, Wendy Weis, Bharti Shah, Eric Lawitz, Robert Schmouder	2025	0
4	#4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS Nephrology Dialysis Transplantation ·Robert Schmouder, Giulia Lestini, Christian Bartels, Irina Baltcheva, G. Junge, Kenneth Kulmatycki	2023	2
5	#4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS Nephrology Dialysis Transplantation ·Robert Schmouder, G. Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki	2023	1
6	Results of Preclinical Animal Studies to Evaluate the Effect of Iptacopan on Pregnancy-Related Outcomes Blood ·Anthony M. DeLise, Natasa Zamurovic, Regine Hansen, Thierry D. Flandre, Robert Schmouder, Chiara Buono	2023	1
7	A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101) Blood ·Robert Schmouder, G. Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki	2023	2
8	#3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN Nephrology Dialysis Transplantation ·Robert Schmouder, G. Junge, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki	2023	3
9	Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? Clinical Drug Investigation ·Christiane Michel, Emil Scosyrev, Michael Petrin, Robert Schmouder	2017	77
10	Brain distribution of BZM055, an analog of fingolimod (FTY720), in human Multiple Sclerosis Journal ·Gilles Tamagnan, Adriana Tavares, Olivier Barret, D Alagille, John Seibyl, Kenneth Marek, R. P. Maguire, Emmanuelle Briard, Robert Schmouder, Rhett Behrje, Danna Jennings	2012	10
11	Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants The Journal of Clinical Pharmacology ·Kai Wu, François Mercier, Olivier David, Robert Schmouder, Michael Looby	2011	14
12	Ethnic sensitivity study of fingolimod in white and Asian subjects International Journal of Clinical Pharmacology and Therapeutics ·John M. Kovarik, Alan Slade, Bryan Voss, Heinz Schmidli, Gilles‐Jacques Rivière, Franck Picard, Yasumasa Sugita, Ryoko Kawai, Denis Mee-Lee, Robert Schmouder	2007	20
13	Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects Biopharmaceutics & Drug Disposition ·John M. Kovarik, Stefan Hartmann, Michael G. Bartlett, Gilles‐Jacques Rivière, Daniel Neddermann, Yibin Wang, Andreas Port, Robert Schmouder	2007	40
14	Everolimus drug interactions: application of a classification system for clinical decision making Biopharmaceutics & Drug Disposition ·John M. Kovarik, D. Beyer, Robert Schmouder	2006	38
15	Absorption characteristics of EC-MPS an enteric-coated formulation of mycophenolic sodium International Journal of Clinical Pharmacology and Therapeutics ·Wolfgang Arns, Martin Gies, Leena Choi, Weifeng Zhu, Patricia A. Cooper, C M Yeh, Pallavi Prasad, P. Gräf, Robert Schmouder	2006	12
16	FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure‐Response Relationship The Journal of Clinical Pharmacology ·Andrej Skerjanec, Hélio Tedesco‐Silva, Hans‐H. Neumayer, Edward Cole, Klemens Budde, Chyi‐Hung Hsu, Robert Schmouder	2005	31
17	Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects The Journal of Clinical Pharmacology ·John M. Kovarik, Robert Schmouder, Denise Barilla, Gilles‐Jacques Rivière, Yibin Wang, Thomas L. Hunt	2004	76
18	PROGNOSIS AFTER PRIMARY RENAL TRANSPLANT FAILURE AND THE BENEFICIAL EFFECTS OF REPEAT TRANSPLANTATION Transplantation ·Akinlolu Ojo, Robert A. Wolfe, Lawrence Y. Agodoa, Philip J. Held, Friedrich K. Port, Sean F. Leavey, Sandra Callard, David M. Dickinson, Robert Schmouder, Alan B. Leichtman	1998	199
19	PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST Transplantation ·D. Kim Turgeon, Alan B. Leichtman, Debbie S. Blake, Robert Schmouder, Kenneth S. Lown, Thomas M Annesley, Paul B. Watkins	1994	19
20	Hyperkinetic borderline hypertension in Tecumseh, Michigan Journal of Hypertension ·Stevo Julius, Lisa Krause, Nicholas J. Schork, Agnes D. Mejia, Kerin A. Jones, Cosmas van de Ven, Ernest H. Johnson, M. Abed Sekkarie, Sverre E. Kjeldsen, Jurij Pétrin, Robert Schmouder, Rakesh Gupta, James C Ferraro, Pietro Nazzaro, Joel L. Weissfeld	1991	181

About Robert Schmouder

Robert Schmouder is a scholar working on Transplantation, Nephrology, Hematology, Immunology and Pharmacology, having authored 93 papers that have together received 5.4k indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (33 papers), Renal Transplantation Outcomes and Treatments (24 papers), Complement system in diseases (16 papers), Drug Transport and Resistance Mechanisms (10 papers), Pharmacological Effects and Toxicity Studies (8 papers), Multiple Sclerosis Research Studies (8 papers), Neurological Complications and Syndromes (7 papers) and Platelet Disorders and Treatments (7 papers). The work is most often cited by research in Transplantation (1.3k citations), Nephrology (555 citations), Pathology and Forensic Medicine (729 citations), Immunology (765 citations) and Molecular Biology (2.2k citations). Robert Schmouder has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Akinlolu Ojo, Friedrich K. Port, Philip J. Held, Robert A. Wolfe, John M. Kovarik, Volker Brinkmann, Peter Heining, Andreas Billich, Shreeram Aradhye and P Burtin. Their work appears in journals such as Transplantation, The Journal of Clinical Pharmacology, Blood, Journal of Hypertension and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact